Results

1–10 of 73 results for Geographic Atrophy

Association of Metformin Use and New-Onset of ICD-Coding of Geographic Atrophy
Dimitra Skondra, MD,PhD
Annual Meeting Talks
2024
Quantitative Contrast Sensitivity Longitudinal Changes Correlate Better Than Visual Acuity With Geographic Atrophy Progression
John B. Miller, MD
Annual Meeting Talks
2024
Multiwavelength Photobiomodulation Significantly Reduces Risk for Vision Loss and Onset of Geographic Atrophy in Dry Age-Related Macular Degeneration
Eleonora Lad, MD, PhD
Annual Meeting Talks
2024
Preservation of Vision by ANX007: Clinical Results and Anatomic Changes From the Phase 2 ARCHER Trial
Joel Pearlman, MD, PhD
Annual Meeting Talks
2024
Pooled Safety Analysis and Immunogenicity of a Single Intravitreal Injection of JNJ-1887 (Gene Therapy, AAVCAGsCD59) in Patients With AMD
Christine Kay, MD
Annual Meeting Talks
2024
Results From Part 1 of the Phase 2/3 SIGLEC Trial Assessing AVD-104 for Geographic Atrophy: Glyco-immunologic Modulation of Macrophage Activity
Rishi P. Singh, MD
Annual Meeting Talks
2024
Fas Inhibition With ONL1204 for the Treatment of Geographic Atrophy: First-Time Results From a Phase 1b Study
Durga Borkar, MD
Annual Meeting Talks
2024
Predictive Role of Outer Retinal Tubulation in Lesion Growth for Subfoveal and Nonsubfoveal Geographic Atrophy
Srinivas Sai A Kondapalli, MD
Annual Meeting Talks
2024
Pegcetacoplan vs Avacincaptad Pegol in Geographic Atrophy: Anchored Matching-Adjusted Indirect Comparisons of Three Phase 3 Trials Over 24 Months
Paul Hahn, MD, PhD, FASRS
Annual Meeting Talks
2024
Characterization of Eyes With Geographic Atrophy That Developed Macular Neovascularization in the GATHER Clinical Trials
Dilraj S Grewal, MD, FASRS
Annual Meeting Talks
2024